CEO James Rosen (Artizan)
Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria
As a Yale spinout based in New Haven, Artizan Biosciences was pretty familiar with Biohaven — a successful neuro-focused drug developer and “shining star,” as Artizan …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.